TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04585906

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Common Elements Treatment Approach
Description: The intervention integrates psychoeducation and addresses safety (when identified as a problem area). It also includes relaxation techniques, problem solving, and cognitive coping.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach
Description: The intervention integrates psychoeducation and addresses safety (when identified as a problem area). It also includes relaxation techniques, problem solving, and cognitive coping.
Study: NCT05703282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-104-A
Description: PO, Single-Dose, AD-104-A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-104-A
Description: PO, Single-Dose, AD-104-A
Study: NCT05447546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HT-6184
Description: Oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HT-6184
Description: Oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HT-6184
Description: Oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HT-6184
Description: Oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HT-6184
Description: Oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HT-6184
Description: Oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HT-6184
Description: Oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HT-6184
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HT-6184 Placebo
Description: Oral capsule
Study: NCT06119646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm Pads Applied to the Breast
Description: Applying a warm pad to a breast during episiotomy repair
Study: NCT05450042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SELUTION SLR DCB
Description: Sirolimus DCB

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel DCB
Description: Paclitaxel DCB
Study: NCT05447546

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HT-6184 Placebo
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HT-6184 Placebo
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HT-6184 Placebo
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HT-6184 Placebo
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HT-6184 Placebo
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HT-6184 Placebo
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HT-6184 Placebo
Description: Oral capsule
Study: NCT05046938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational İnterviewing
Description: Students with food addiction will be provided with motivational interviews about food addiction in 5 sessions, each of which varies between 6-8 groups.
Study: NCT06281691

Intervention type: DIAGNOSTIC_TEST
Intervention: Xpert® Bladder Cancer Detection Test
Description: A urine sample is analyzed with the Xpert® Bladder Cancer Detection Test
Study: NCT05571943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difamilast
Description: Difamilast Ointment 1%
Study: NCT05305144

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vascular and ophthalmological examinations
Description: Part. 1 - Vascular checkup examinations:~After collecting classic clinical parameters (weight, height, waist circumference), the in-depth vascular workup of each participant will include the following measurements:~* Measurement of central arterial pressure,~* Measurement of arterial stiffness,~* Continuous blood pressure measurement (beat-to-beat),~* Heart rate measurement,~* 24-hour blood pressure measurement with QKD (holter).~Part. 2 - Ophthalmological examinations:~After dilating the pupil, a series of examinations will be conducted on the participant:~* Auto-refractometry~* Measurement of the axial length of the globe~* Color retinophotography of the retina,~* Adaptive Optics Exam~* SS-OCT-A exam
Study: NCT04986553

Intervention type: DEVICE
Intervention: Arthrex Clavicle Plates
Description: Arthrex Clavicle Plate for treatment of clavicle fractures
Study: NCT05529628

Intervention type: DIAGNOSTIC_TEST
Intervention: Cytokine levels
Description: Preoperative cytokine levels of the patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Cytokine levels
Description: Preoperative cytokine levels of the patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Cytokine levels
Description: Preoperative cytokine levels of the patients
Study: NCT05547100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYBALVI
Description: 5 mg Olanzapine/10 mg Samidorphan dose approved for use in treatment for schizophrenia and bipolar I disorder
Study: NCT05840666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Sustained Natural Apophyseal Glide (SNAG)
Description: Application of the MWM technique developed by Brian R. Mulligan. The clinical researcher will perform and holds sustained passive segmental glide at the target joint maintaining the slack whereas the patient will actively move in the direction of pain or stiffness. These MWM techniques when applied to spinal segments or joint is called sustained natural apophyseal glide (SNAG).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McKenzie Method
Description: An active therapy technique involving repeated movements or sustained positions along with an educational component prescribed to the patient for of minimizing the pain and disability and increase the spinal range of motion. The method will involve the assessment of symptomatic and mechanical responses to repeated movements and sustained positions in the direction of preference. The method will be used for assessment and treatment of patients and with derangement syndrome.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: It includes usual physical therapy care such as Therapeutic Ultrasound, Moist Heat-pack, TENS and standard exercises.
Study: NCT05685108

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound stimulation intensity
Description: A clinical ultrasound transducer will be placed against the abdomen or neck of an individual in order to administer insonification to the splenic nerve.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound stimulation site
Description: A clinical ultrasound transducer will be placed against the abdomen or neck of an individual in order to administer insonification to the splenic nerve and the cervical vagus nerve.
Study: NCT05056103

Intervention type: DEVICE
Group type: OTHER
Intervention: TrachFlush
Description: The attending nurses activate the TrachFlush when there are secretions present in the larger airways that need to be removed. If this results into a push of airway secretions past and above the cuff of the endotracheal tube, no further action is needed. If unsuccessful, the nurse will perform a standard tracheal suctioning procedure to remove the secretions. In a subset of patients with an endotracheal tube that allows subglottal suctioning, the exact amount of airway secretions present above the cuff will be measured each time the TrachFlush is used.
Study: NCT06526572

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain wave analysis using electroencephalography (EEG).
Description: Asessment of pain with objective neurophysiological assessment through brain wave analysis using electroencephalography (EEG).

Intervention type: DIAGNOSTIC_TEST
Intervention: Numerical rate Scale (NRS)
Description: Asessment of pain with the subjective numercal rate scale method (NRS
Study: NCT04727866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous spinal direct current stimulation (tsDCS) - coronal
Description: 20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with cathode over C5-C7 transverse process on target side, anode over C5-C7 transverse process on non-target side.
Study: NCT06089850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluate the evolution of the psychic state of the donors (ascendants and descendants), by means of questionnaires, within the framework of haplo-identical allograft.
Description: Donors are included in the study during the pre-donation assessment. Completion of questionnaires + socio-demographic data~CSH collection visit (V1): Visit at which donors are collected for CSH donation. Completion by the donor of the questionnaires~Follow-up of donors at D90 (+/-7) post V1, D180 (+/-15D) post V1 and D360 (+/-15D) post V1. The donors participating in the study will complete the scales/questionnaires~D360: Completion by the donor of the questionnaires + semi-structured interview by telephone if accepted by the participant
Study: NCT05081752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OTSC Stentfix
Description: Stent placement with fixation of the esophageal stent using OTSC Stentfix.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stent Suturing / Endoscopic Clips
Description: Stent placement with fixation of the esophageal stent using sutures / endoscopic clips.
Study: NCT04727866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous spinal direct current stimulation (tsDCS) - caudal
Description: 20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with DCS cathode over \~T1-T4 posteriorly, anode over \~C5-T1 anteriorly

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous spinal direct current stimulation (tsDCS) - rostral
Description: 20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with DCS cathode over \~C3-C5 posteriorly, anode over \~C5-T1 anteriorly

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS)
Description: 3 minutes of iTBS (a form of repetitive TMS) will be delivered during a 5-minute interval of DCS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS)
Description: 3 minutes of iTBS (a form of repetitive TMS) will be delivered during a 5-minute interval of DCS
Study: NCT04106999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Drug infusion will be delivered intra-operatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Normal Saline will be infused as a control drug
Study: NCT04842357

Intervention type: OTHER
Group type: OTHER
Intervention: standardised video concerning clinical skill
Description: watching a video concerning clinical skills.

Intervention type: OTHER
Group type: OTHER
Intervention: standardised video concerning clinical skill
Description: watching a video concerning clinical skills.
Study: NCT06130059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Colchicine
Description: Colchicine has been demonstrated to improve cardiovascular outcomes among patients with cardiovascular disease. In the COLCOT trial, the use of low-dose colchicine resulted in a reduction of major adverse cardiovascular events among participants with recent MI. The trial demonstrated the utility of anti-inflammatory therapies in improving cardiovascular outcomes. Colchicine has been widely used for decades and its safety profile is well established.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04862143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Participants received a daily oral dose of 300 mg of alpelisib film-coated tablets for a total of 12 cycles, with each cycle lasting 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Participants were administered fulvestrant at a dose of 500 mg via intramuscular injection on Cycle 1 Day 1 and Cycle 1 Day 15, and on Day 1 of each 28-day cycle thereafter until Cycle 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Pre-menopausal women were administered a dose of 3.6 mg of goserelin injection via intramuscular route, beginning on Cycle 1 Day 1. Subsequently, the same dose was administered on Day 1 of each 28-day cycle throughout the study.
Study: NCT05260983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Education and Acceptance and Commitment Therapy
Description: A brief diabetes prevention education and acceptance and commitment therapy engagement facilitation intervention. Acceptance and Commitment Therapy-informed materials (i.e. video, workbook, and activities) will retain facts about the condition, but will modify health messaging to clarify common inaccurate illness perceptions, reduce body size discrimination, and encourage psychological flexibility through framing illness perceptions, controllability awareness (i.e. ability to distinguish modifiable from unmodifiable components), non-judgmental awareness of what is occurring, willingness to allow experiences to occur, and the ability to step back from cognitions, acting according to personal values.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Prevention Education Only
Description: A brief standard diabetes prevention education engagement facilitation intervention modeled from the Center for Disease Control and Preventions's National Diabetes Prevention Program.
Study: NCT05164822

Intervention type: OTHER
Intervention: Necrotizing Vasculitis
Description: Pain scale Diagnosis of necrotizing vasculitis and peripheral neuropathy, Clinical characteristics of the disease, Biological analysis, Treatment and evolution of the disease,~Questionnaires :~Neuropathy Impairment Score (NIS) sensitive sub-questionnaire that measures extremity sensitivity.~MRC (Medical Research Council), which evaluates three motor functions on each member.~RODS questionnaire on the relationship between your daily activities and your health.~BVAS (Birmingham Vasculitis Activity Score) disease activity questionnaire. VDI (Vasculitis Damage Index) questionnaire evaluates the sequelae of the disease.~Rankin Score modified to measure the degree of disability~Two tests will be performed:~EMG (electromyogram) to evaluate the electrical activity of the muscles, Walking Test of 10 meters which aims to measure the time taken to travel 10 meters.
Study: NCT06538636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCP-Facing Tools
Description: PCP-facing tools will be turned on as a package: a) enhanced LCS clinical reminder including DP+ generated smart message; b) Integrated one-click DP+ full decision tool for automating personalized information about the net benefit of LCS based on patient characteristics; c) the TurboHM tool: automated Health maintenance app for tracking all preventive care, including a dedicated LCS section with personalized information

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCP-Facing Tools
Description: PCP-facing tools will be turned on as a package: a) enhanced LCS clinical reminder including DP+ generated smart message; b) Integrated one-click DP+ full decision tool for automating personalized information about the net benefit of LCS based on patient characteristics; c) the TurboHM tool: automated Health maintenance app for tracking all preventive care, including a dedicated LCS section with personalized information

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCP-Facing Tools
Description: PCP-facing tools will be turned on as a package: a) enhanced LCS clinical reminder including DP+ generated smart message; b) Integrated one-click DP+ full decision tool for automating personalized information about the net benefit of LCS based on patient characteristics; c) the TurboHM tool: automated Health maintenance app for tracking all preventive care, including a dedicated LCS section with personalized information

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LCS team population management tools
Description: site-specific dashboard and proactive outreach toolkit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LCS team population management tools
Description: site-specific dashboard and proactive outreach toolkit

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LCS team population management tools
Description: site-specific dashboard and proactive outreach toolkit
Study: NCT05734508

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN vaccine
Description: A live vaccine produced from the Modified Vaccinia Ankara-Bavarian Nordic strain (MVA-BN), an attenuated and non-replicating orthopox virus
Study: NCT04200066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide, Tamoxifen, Maprotiline
Description: Subjects will receive a combination of temozolomide and tamoxifen for two weeks. After that, they will receive a combination of temozolomide, tamoxifen and maprotiline for the remainder of the study. All drugs are administered orally. Subjects will undergo visits at the beginning of week 3, week 5 and week 7 that will involve multiple blood draws and ECGs to evaluate for pharmacokinetics and drug interactions. Response will be assessed every two months with an MRI and patients will continue on study as long as their tumors are under control and they are tolerating the regimen.
Study: NCT02629237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifaceted education
Description: Subjects will be asked to watch a 5-10 min education film and participate in a 10-15 min counseling session with a trained doctor/nurse before glaucoma surgery,and at 1 week and 2 week after surgery.
Study: NCT04800029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth in preventing suicide (TIPS)
Description: The TIPS synchronous telehealth protocol will consist of (a) two-way televideo evaluation with enhanced suicide risk components, performed by a Masters-level evaluator from Community HealthLink, and (b) telephone consultation and, in some cases, televideo evaluation by a psychiatrist for patients the evaluator judges should be admitted. The primary evaluation will gather data form the ED providers, patient, and any other collateral sources available. The core of the evaluation itself will consist of Community HealthLink's existing standard adult emergency mental health evaluation, which is a semi-structured evaluation focused primarily on informing a disposition decision on whether to admit the patient to a psychiatric unit. The evaluators will use this same evaluation to guide the telehealth evaluation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth in preventing suicide (TIPS)
Description: The TIPS synchronous telehealth protocol will consist of (a) two-way televideo evaluation with enhanced suicide risk components, performed by a Masters-level evaluator from Community HealthLink, and (b) telephone consultation and, in some cases, televideo evaluation by a psychiatrist for patients the evaluator judges should be admitted. The primary evaluation will gather data form the ED providers, patient, and any other collateral sources available. The core of the evaluation itself will consist of Community HealthLink's existing standard adult emergency mental health evaluation, which is a semi-structured evaluation focused primarily on informing a disposition decision on whether to admit the patient to a psychiatric unit. The evaluators will use this same evaluation to guide the telehealth evaluation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified ED-SAFE
Description: Half of the ED discharged patients with suicide risk will be invited to receive post-discharge telephone counseling originally developed during the Emergency Department Safety Assessment and Follow-up Evaluation (ED-SAFE) study. The participant will receive three coaching/counseling calls, clustered within three months of the index visit, with some flexibility to continue beyond that if desired. These coaching calls will still follow the original structure and content from ED-SAFE, with modifications guided by study investigators.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: No study related intervention, just monitoring of current practices used to provide suicide-related care in the non-intervention EDs.
Study: NCT05639738

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical and instrumental measurements
Description: * Clinical evaluations~* Non-invasive instrumental measurements~* Subject's evaluations
Study: NCT05481021

Intervention type: OTHER
Intervention: No intervention but assessing for burnout syndrome in all group
Description: Using Maslach Burnout inventory to assess the presence of burnout and a self reporting questionnaire to identify possible stressors or associations
Study: NCT05524194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Infusion
Description: Dose-limiting toxicity (DLT) are assessed during the first 3 weeks (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks (Q2W).
Study: NCT05877001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg, IV, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: 80 mg once daily for the first 3 weeks of each 4-week cycle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HAIC
Description: OXA 85mg/m2 IA 0-4h +5-Fu 2000mg/m2 IA 4-48h，CF 200mg/m2 IV 2-4h， Q3W
Study: NCT04479618

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Practice
Description: A saline soaked piece of gauze, conformed to the size of the open ulcer area, will be placed over the ulcer and held in place with a wrap of stretch gauze. Ulcers will be rinsed with saline at daily dressing changes, which will be conducted by the patient after they master the procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Improvised dressing
Description: A piece of a new food-grade plastic bag, cut slightly larger than the ulcer, will be placed over the ulcer, sealed at the edges with an emollient to create an occlusive dressing. The dressing will be gently conformed to the ulcer contours to eliminate dead space, and a slit will be cut in the center to allow excess fluid to escape into a clean absorbent material placed over the slit. The device will be held in place with a wrap of stretch gauze. Ulcers will be rinsed with saline at daily dressing changes, which will be conducted by the patient after they master the procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Advanced dressing
Description: A piece of polymeric membrane dressing, cut to extend at least 0.5cm beyond the open ulcer edges, will be placed over the ulcer and held in place with a wrap of stretch gauze. The approximate wound edges will be marked on the back of the dressing. Dressing changes will consist only of removing the dressing when the saturation level, visible through the wound backing, reaches the mark indicating the dressing edges and applying a new cut dressing. Changes will be conducted by the patient after they master the procedure.